Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $18.50.

AQXP has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Saturday, March 11th.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.14% during midday trading on Monday, reaching $14.12. The company had a trading volume of 54,513 shares. Aquinox Pharmaceuticals has a one year low of $6.01 and a one year high of $19.97. The company has a 50 day moving average of $16.09 and a 200 day moving average of $15.44. The company’s market capitalization is $330.73 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Thursday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. Analysts predict that Aquinox Pharmaceuticals will post ($2.22) EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. TD Asset Management Inc. acquired a new stake in shares of Aquinox Pharmaceuticals during the third quarter worth about $1,052,000. BlackRock Advisors LLC increased its stake in shares of Aquinox Pharmaceuticals by 31.1% in the third quarter. BlackRock Advisors LLC now owns 530,373 shares of the company’s stock worth $7,086,000 after buying an additional 125,798 shares during the last quarter. BlackRock Inc. increased its stake in shares of Aquinox Pharmaceuticals by 32.0% in the third quarter. BlackRock Inc. now owns 66,792 shares of the company’s stock worth $892,000 after buying an additional 16,192 shares during the last quarter. BlackRock Group LTD increased its stake in shares of Aquinox Pharmaceuticals by 15.9% in the third quarter. BlackRock Group LTD now owns 232,002 shares of the company’s stock worth $3,100,000 after buying an additional 31,902 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Aquinox Pharmaceuticals by 227,925.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,121 shares of the company’s stock worth $122,000 after buying an additional 9,117 shares during the last quarter. 97.78% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/analysts-set-aquinox-pharmaceuticals-inc-aqxp-pt-at-18-50/1206002.html.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

5 Day Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.